LetsGetChecked

Are you interested in staying on top of the latest health trends, insights, and innovations? Then sign up for our newsletter! At LetsGetChecked, we are dedicated to empowering your populations to take control of their health and well-being through accessible testing, virtual care, genetic sequencing, and medication delivery. Our newsletter has something for everyone. By subscribing, you'll gain access to: ✅ Exclusive content curated by health experts ✅ Updates on new testing options and services ✅ Inspiring stories from our community Join us on our mission to make proactive health management accessible to all by subscribing to our newsletter today: https://lnkd.in/gu23ktmE

“LetsGetChecked ImPress” was honored in Fast Company’s Innovation by Design Awards for 2024 in the Health category. LetsGetChecked ImPress, which adheres directly to the skin and uses a gentle vacuum suction to extract up to 600uL of blood in minutes, is designed to be used during at-home sample collection or in clinical point of care settings. It is currently available for research-use only. The Innovation by Design Awards, which can be found in the Summer 2024 issue of Fast Company, honor the designers and businesses solving the most crucial problems of today and anticipating the pressing issues of tomorrow. The competition, now in its 13th year, features a range of blue-chip companies, emerging startups, and promising young talent. It is one of the most sought-after design awards in the industry. You can check out the complete list of #FCDesignAwards health category honorees at the link below!

Chlamydia and gonorrhea are two of the most commonly reported bacterial sexually transmitted infections (STIs) in the United States. Multi-site screening for these STIs can help increase the likelihood of detecting infections, especially in individuals who may be asymptomatic or have infections located in less commonly tested anatomical sites. Read this week’s blog to learn more about multi-site sexual health testing for chlamydia and gonorrhea and how home sample collection options can improve access to more comprehensive care and reduce the risk of missed infections.

Improving access to sexual healthcare is crucial, especially for sexually transmitted infections (STIs). A recent LetsGetChecked study validated home sample collection for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) from rectal and throat sites. Our study showed high agreement between self-collected and provider-collected samples. Detection was unaffected by common hand contaminants, storage time, or extreme temperatures. This supports the reliability of self-collection for extragenital STI testing, benefiting the LGBTQ community. LetsGetChecked integrates these methods, enhancing its accessible and accurate STI screening solutions. Discover more here: https://lnkd.in/eEFv4AWM

Join Michael Rummel, our Chief Laboratory Officer, as he shares an exclusive look inside our state-of-the-art, CLIA-certified, and CAP-accredited laboratory in Monrovia, California. Ownership of our laboratory infrastructure allows us to design panels optimized for specific patient needs and adapt our catalog to scale freely. With both predictive and screening tools at our disposal, we can identify potential health issues as well as  anticipate them, enabling proactive patient care. This unique approach empowers our patients to live longer, happier lives. Check it out!

Offering individuals the ability to manage their healthcare from the comfort of their homes has long been a goal for healthcare systems, pharmaceutical companies, consumers, and patient advocacy groups alike. Check out our interview with our Head of Life Sciences, Joe Keenan, to explore at-home healthcare solutions and how pharmaceutical companies can choose a partner to deliver safe and reliable solutions that engage easily and improve patient experiences.

Reliable lead screening is crucial for early detection of lead exposure in children. A LetsGetChecked study highlights the effectiveness of using dried blood spots (DBS) for this purpose, presenting a strong alternative to traditional venipuncture and capillary collection methods. Conducted across three independent clinical laboratories, the research compared three DBS inductively coupled plasma-mass spectrometry (ICP-MS) methods and found that using matrix-matched DBS calibrators significantly enhanced performance. The study demonstrated a strong correlation between lead levels measured in DBS and whole blood, affirming DBS ICP-MS as a robust and accurate method for lead screening. This advancement underscores the value of external quality control programs in evaluating DBS methods, making it a promising tool in pediatric health screening. Thank you Rogers A. Muldrow, one of our Research and Development Scientists, for your dedication and contribution to the publication of this study. Discover more here: https://lnkd.in/ejG_s7-Z

When we visited Novartis UK’s offices for a heart health presentation in support of British Heart Week, we provided their employees with complimentary heart health and Lipoprotein(a) screening to underscore the importance of taking charge of your heart health and identifying personal risks early on. Being aware of your Lp(a) levels and regularly testing your cholesterol levels is crucial in preventing cardiovascular disease and managing overall heart health effectively.

According to the study “At-Home Diagnostics Solutions for Chlamydia and Gonorrhea” by Ellen Kersh, PhD, D(ABMM) and Leandro Mena, STIs, particularly chlamydia and gonorrhea, remain significant public health challenges in the United States. Traditional testing methods often face barriers such as accessibility and stigma, leading to persistently low screening rates, especially in under-resourced areas. It was great to see our FDA DeNovo authorized Simple 2 Test, which tests for gonorrhea and chlamydia through vaginal swab or urine sample from at-home collection, highlighted as a solution to address some of these challenges. By removing the barriers to testing, we empower people to take control of their sexual health, ensuring timely detection and treatment of STIs, thereby contributing to better public health outcomes.

We are pleased to share an article co-authored by Dr. Avni Santani, our Chief Genomics Officer, and colleagues at Stanford University that explores the application of whole genome sequencing as a single platform for clinical constitutional genetic testing. As a result of continuous improvements in throughput and cost effectiveness, whole genome sequencing is rapidly becoming a platform of choice for comprehensive genetic testing. This review evaluates the utility of genome sequencing in a range of applications including diagnostic testing, carrier screening, prenatal testing, risk assessment  and cytogenomics. Discover more at the link below: https://lnkd.in/e6a2wB3m